Member Info for Jace86

A little promotion wouldn't hurt. Especially with their options.

I do believe we have wrong footed ourselves expecting a CLIA RNS when it simply should be an announcement of a lab using the test as and when that comes about.

Enough people now I'm place in BIO for them to be ramping up their own PR (that we won't see directly and will need to be observant for).

If the comms come forward a bit and there's a bit more proactivity, we'll see a lift in SP. I know they might not like that type of thing but at this end of the market, it is necessary.

Yep there will be those with larger holds privy to strategy but their SP won't move either unless there is a wider reach in terms of Comms.

The markets have been more alive recently and people are out bargain hunting. Tech and science stocks are often missed for the gold, oil and stones that are easier to shout about.

Keep it simple and they can attract the buyers.

A question I've asked in the TG group that one responded to.

Seeking further view here...

We are waiting for CLIA.

What if we don't need it because we are intending on using a lab that already has one?

Simple concept. You don't need a CLIA per test. It is per lab.

BIO are in charge of what/who is being used. We don't have to be told as such any more than the licensing agreement.

Curious as to what others may think...

You complain about this not being able to hold its price and yet anyone wanting to research this share and trying to get starting points on this board is forever met with your posts and mentions of CDT.

Take that s**t to the Vela board.

For us, CDT is a tiny side show.

People onlooking, look at Greend100's posts below.

Now let's do the numbers. Royalty at ten percent. Don't even look at ownership of BIO as it's another conversation entirely.

Over 14 million eligible. That's just the US and the licence is for the entirety of the North American continent and the Caribbean.

Test expected to be 200-300. Just think about there being just a mere million tests per year here alone... That's a six figure mcap. BIO getting bigger with major names being published weekly.

Then China, where they might even mandate the screening. 100 per test again with ten percent royalty. Bosch and Sinopharm will lead the way. Big firms.

We've not even got to Europe yet...

Then factor in firms like Bio-Techne working with us and having their machines ready to go to do the testing with... Etc.

We aren't dealing with little no names here or some little p*ss pot spin off that the majority of posters aren't bothered about.

You miss my point on it being a bonus. Had we not known about the equity stake and merely licensed out the product, we'd be none the wiser.

Having the equity on a company that appears to be taking things seriously is a bonus on top of them going for it with the launch.

I think we (me included) forget that the equity stake is actually a bonus.

It's the revenue that will matter. So the volumes that do get sold.

It looks like three things spooked the price. Not sells themselves simply as they aren't heavy enough.

Firstly the US trade war. Tariffs shouldn't be an issue for us. We are manufacturing and distributing in the US via Cizzle BIO.

Firms with big cash burns delisting. LLAI for example.

Lastly, the deadline self imposed by BIO went quiet. They simply don't have to tell *us* immediately. Read that and read it again.

Sit and wait.

Market makers would be prudent to allow trading upwards if they intend to make money here. They are partly to blame for broken markets.

Probably why the work is done in the US... The Texas agreement saw this coming.

The positive sentiment and useful posts keep getting buried beneath your posts, Joey.

Onlookers and potential new speculators won't look too far. If all they see is the negative post they don't research much further than that.

Reads very well, especially this section:

The timing of this appointment coincides with the successful completion of the technical programme which confirms that the most cost-effective and scalable version of the CIZ1B biomarker assay for CLIA accreditation is an ELISA. The rigorous quality control programme undertaken has been able to demonstrate equivalence with initial manual laboratory tests and with the BioTechne ProteinSimple capillary Western system. Results have shown sensitivity equivalent to published CIZ1B lung cancer studies, and an ability to correctly identify people with lung cancer with few false negative results."

No, no one else is as worried as you and all of your multiple IDs.

The issue with your posts is that good quality information that people can draw on gets lost very easily. Even when they block you and only see green box after green box.

Either way, whilst it looks like it could be either way it's material to the valuation of the company.

The company should RNS if these category B shares are in addition to what we had already been expecting.

Sentiment is everything at this end of the market.

Wid - what's the company doing wrong?

Or is it a case of the favourite pumpers and dumpers aren't trying to flip a forward sold placing...?

It's not the company. Not sure what else they can do.

They've laid out the timescales in a recent RNS.

The issue is that they don't need the usual pump n dump crews to spike the price like the miners and oilers.

Instead they've backing off people actually interested in the outcome.

In the latest interview too, BIO didn't wait until the MOU was completed. They cracked on regardless.

It depends on the relationship between BIO investors and BIO.

They aren't under an obligation to state how much, who from or even what for.

We knew the MOU was going to convert but we won't have a full itinerary of BIOs plans as we are effectively a passenger.

I do believe they'll get motoring. Mr Behnke likes Yachts and Bentleys... 😉

The honest answer is that we don't know.

We aren't ciz bio. They don't have to answer to us.

I'd look at who they've appointed recently and see if there is any information in the public domain, any clues as to where they are intending on heading and whether there are any partners lined up to take on this test...

The extension wasn't for "another investment" but to accelerate or to go beyond their initial remit.

O+G and explorers in general are money pits that rely on placings and pumps.

This is why they tend to have a better profile with volume.

Also where most lose their money....

There is correlation there.

Most retail investors don't know how to compare this product to what is already out there and the timescales for other competitors. We've seen it plenty of times on this board.

It isn't straightforward but when people do a bit of digging, they should see the potential.

The initial risk is out of the way on finding and one territory is now effectively signed up.

Some may take time later to review the company thoroughly and now Ciz Bio too in order to understand the potential.

This still reads that everything is on track.

Not sure why people are seeing something negative.

Accreditation we was told would be around November.

Also someone asked about royalty. It's there in black and white.

"Cizzle has received an upfront royalty payment of US$300,000 as part of a 10% royalty on gross sales after tax, with guaranteed minimum royalty payments totalling US$2 million over the next 30 months."

We knew how that was going to end...

Serious names in BIO and awaiting update on patent that I'm hoping isn't far off now...

All telegram groups got subjected to a bot add spam function.

Anyone that was in the old group please DM me for a new link.